Danner, Bernhard

[["dc.bibliographiccitation.artnumber","e16712"],["dc.bibliographiccitation.issue","31"],["dc.bibliographiccitation.journal","Medicine"],["dc.bibliographiccitation.volume","98"],["dc.contributor.author","Buentzel, Judith"],["dc.contributor.author","Yao, Sha"],["dc.contributor.author","Elakad, Omar"],["dc.contributor.author","Lois, Anna-Maria"],["dc.contributor.author","Brünies, Jana"],["dc.contributor.author","König, Julia"],["dc.contributor.author","Hinterthaner, Marc"],["dc.contributor.author","Danner, Bernhard C."],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Emmert, Alexander"],["dc.contributor.author","Bohnenberger, Hanibal"],["dc.date.accessioned","2019-08-09T06:40:34Z"],["dc.date.available","2019-08-09T06:40:34Z"],["dc.date.issued","2019"],["dc.description.abstract","Molecular characterization of lung cancer specimens after radical surgery offers additional prognostic information and may help to guide adjuvant therapeutic procedures. The transcriptional regulators alpha thalassemia/mental retardation X-linked (ATRX) and death domain-associated protein (DAXX) have recently been described in different cancer entities as a useful prognostic biomarker. This study was initiated to explore their protein expression patterns and prognostic value in patients with operable lung cancer disease.The protein abundance (in the following text also named protein expression) of ATRX and DAXX were analyzed by immunohistochemistry in 194 samples of squamous cell lung carcinoma (SQCLC), 111 samples of pulmonary adenocarcinoma (AC) and 40 samples of small cell lung cancer (SCLC). The protein levels of ATRX and DAXX were correlated with clinicopathological characteristics and patient outcome.ATRX showed strong protein expression in 16.2% of AC, 11.9% of SQCLC, and 42.5% of SCLC. DAXX was highly expressed in 54.9% of AC, 76.2% of SQCLC, and 82.5% of SCLC. Immunostaining of both ATRX and DAXX were seen in 14.4% of AC, 11.3% of SQCLC, and 42.5% of SCLC. High protein expression of ATRX was a favorable prognostic marker for patients with AC (hazard ratio 0.38, P = .02). Sub-group analyses showed a significant correlation between ATRX and the clinical stage of SQCLC and SCLC. Histological grading and ATRX were also significantly associated in cases of SQCLC.The presence of ATRX and DAXX are correlated with lung cancer histology. Strong ATRX protein expression is associated with a significantly longer overall survival in patients with AC."],["dc.description.sponsorship","Open-Access-Publikationafonds 2019"],["dc.identifier.doi","10.1097/MD.0000000000016712"],["dc.identifier.pmid","31374064"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16343"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/62353"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","1536-5964"],["dc.relation.issn","0025-7974"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.title","Expression and prognostic impact of alpha thalassemia/mental retardation X-linked and death domain-associated protein in human lung cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","19"],["dc.bibliographiccitation.journal","Cancer Research"],["dc.bibliographiccitation.volume","74"],["dc.contributor.author","Bohnenberger, Hanibal"],["dc.contributor.author","Stroebel, Philipp"],["dc.contributor.author","Henric-Petri, Hannah"],["dc.contributor.author","Lenz, Christof"],["dc.contributor.author","Emmert, Alexander"],["dc.contributor.author","Bremmer, Felix"],["dc.contributor.author","Strecker, Jasmin"],["dc.contributor.author","Holland, Rainer"],["dc.contributor.author","Hinterthaner, Marc"],["dc.contributor.author","Corso, Jasmin"],["dc.contributor.author","Wagner, Sebastian"],["dc.contributor.author","Kueffer, Stefan"],["dc.contributor.author","Sebastian, Martin"],["dc.contributor.author","Bergmann, Lothar"],["dc.contributor.author","Danner, Bernd"],["dc.contributor.author","Schoendube, Friedrich Albert"],["dc.contributor.author","Serve, Hubert"],["dc.contributor.author","Urlaub, Henning"],["dc.contributor.author","Oellerich, Thomas"],["dc.date.accessioned","2018-11-07T09:33:49Z"],["dc.date.available","2018-11-07T09:33:49Z"],["dc.date.issued","2014"],["dc.identifier.doi","10.1158/1538-7445.AM2014-2487"],["dc.identifier.isi","000349906903219"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32050"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Assoc Cancer Research"],["dc.publisher.place","Philadelphia"],["dc.relation.conference","105th Annual Meeting of the American-Association-for-Cancer-Research (AACR)"],["dc.relation.eventlocation","San Diego, CA"],["dc.relation.issn","1538-7445"],["dc.relation.issn","0008-5472"],["dc.title","Comprehensive quantitative proteomic profiling of lung cancers reveals novel biomarkers and potential drug targets"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2523"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Translational Lung Cancer Research"],["dc.bibliographiccitation.lastpage","2538"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Yao, Sha"],["dc.contributor.author","Peng, Luogen"],["dc.contributor.author","Elakad, Omar"],["dc.contributor.author","Küffer, Stefan"],["dc.contributor.author","Hinterthaner, Marc"],["dc.contributor.author","Danner, Bernhard C."],["dc.contributor.author","Hammerstein-Equord, Alexander von"],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Bohnenberger, Hanibal"],["dc.date.accessioned","2021-08-12T07:45:40Z"],["dc.date.available","2021-08-12T07:45:40Z"],["dc.date.issued","2021"],["dc.description.sponsorship","Open-Access-Publikationsfonds 2021"],["dc.identifier.doi","10.21037/tlcr-20-1039"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/88522"],["dc.notes.intern","DOI Import GROB-448"],["dc.relation.eissn","2226-4477"],["dc.relation.issn","2218-6751"],["dc.relation.orgunit","Institut für Pathologie"],["dc.rights","CC BY-NC-ND 4.0"],["dc.title","One carbon metabolism in human lung cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e28814"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Medicine"],["dc.bibliographiccitation.volume","101"],["dc.contributor.author","Tirilomi, Anna"],["dc.contributor.author","Elakad, Omar"],["dc.contributor.author","Yao, Sha"],["dc.contributor.author","Li, Yuchan"],["dc.contributor.author","Hinterthaner, Marc"],["dc.contributor.author","Danner, Bernhard C."],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Tirilomis, Theodor"],["dc.contributor.author","Bohnenberger, Hanibal"],["dc.contributor.author","von Hammerstein-Equord, Alexander"],["dc.date.accessioned","2022-02-23T13:44:43Z"],["dc.date.available","2022-02-23T13:44:43Z"],["dc.date.issued","2022-02-11"],["dc.description.abstract","Lung cancer remains the worldwide leading cause of cancer-related death. Currently, prognostic biomarkers for the detection and stratification of lung cancer are being investigated for clinical use. The surface protein cluster of differentiation 49b (CD49b) plays an important role in promoting cell proliferation and invasion in different tumor entities and blocking CD49b improved the tumor immune response. Overexpression of CD49b has been associated with unfavorable survival rates in several malignant tumor entities, such as prostate cancer, gastric cancer and colon cancer. Therefore, we aimed to analyze the protein expression of CD49b in patients with different types of lung cancer and additionally to identify the influence of CD49b on clinicopathological characteristics and overall survival.Expression levels of CD49b were retrospective analyzed by immunohistochemistry in 92 cases of pulmonary adenocarcinoma (AC), 85 cases of squamous cell lung carcinoma (SQCLC) and 32 cases of small cell lung cancer (SCLC) and correlated with clinicopathological characteristics and patients' overall survival.A strong expression of CD49b was most seen in SQCLC (78%), followed by AC (48%) and SCLC (9%). All patients combined, strong expression of CD49b correlated significantly with poorer overall survival. However, an increased expression of CD49b correlated significantly with a poorer survival rate only in SQCLC. In AC and SCLC, no significant correlation could be demonstrated in this regard.In our study, CD49b expression was associated with poor overall survival in patients with SQCLC. Accordingly, CD49b could serve as a new prognostic biomarker and, moreover, be a potential new drug target in SQCLC."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.doi","10.1097/MD.0000000000028814"],["dc.identifier.pmid","35147120"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/100370"],["dc.language.iso","en"],["dc.relation.eissn","1536-5964"],["dc.relation.issn","0025-7974"],["dc.relation.issn","1536-5964"],["dc.rights","CC BY 4.0"],["dc.title","Expression and prognostic impact of CD49b in human lung cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1841"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","The Annals of Thoracic Surgery"],["dc.bibliographiccitation.lastpage","1843"],["dc.bibliographiccitation.volume","98"],["dc.contributor.author","Emmert, Alexander"],["dc.contributor.author","Jebran, Ahmad Fawad"],["dc.contributor.author","Schmidt, Karsten"],["dc.contributor.author","Hinterthaner, Marc"],["dc.contributor.author","Bohnenberger, Hanibal"],["dc.contributor.author","Bähr, Mathias"],["dc.contributor.author","Schoendube, Friedrich A."],["dc.contributor.author","Danner, Bernhard C."],["dc.date.accessioned","2017-09-07T11:45:25Z"],["dc.date.available","2017-09-07T11:45:25Z"],["dc.date.issued","2014"],["dc.description.abstract","This clinical report deals with a giant true pulmonary venous aneurysm, which was partially thrombosed. The overall incidence of pulmonary venous aneurysms is unknown, and they are reported only occasionally. We present the case of a previously healthy man with acute onset of ischemic cerebral stroke. The cause was a thrombus in a huge aneurysm of the left superior pulmonary vein. The patient subsequently underwent uncomplicated therapy for stroke, including thrombolysis followed by excision of the giant pulmonary venous aneurysm. As curative therapy we recommend complete resection of this rare entity. (C) 2014 by The Society of Thoracic Surgeons"],["dc.identifier.doi","10.1016/j.athoracsur.2013.12.087"],["dc.identifier.gro","3142027"],["dc.identifier.isi","000344746600085"],["dc.identifier.pmid","25441803"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/3734"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Elsevier Science Inc"],["dc.relation.eissn","1552-6259"],["dc.relation.issn","0003-4975"],["dc.title","Aneurysm of the Pulmonary Vein: An Unusual Cause of Stroke"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3574"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Cancer Medicine"],["dc.bibliographiccitation.lastpage","3583"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Elakad, Omar"],["dc.contributor.author","Lois, Anna‐Maria"],["dc.contributor.author","Schmitz, Katja"],["dc.contributor.author","Yao, Sha"],["dc.contributor.author","Hugo, Sara"],["dc.contributor.author","Lukat, Laura"],["dc.contributor.author","Hinterthaner, Marc"],["dc.contributor.author","Danner, Bernhard C."],["dc.contributor.author","Reuter‐Jessen, Kirsten"],["dc.contributor.author","Schildhaus, Hans‐Ulrich"],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Bohnenberger, Hanibal"],["dc.contributor.author","von Hammerstein‐Equord, Alexander"],["dc.date.accessioned","2021-04-14T08:26:56Z"],["dc.date.available","2021-04-14T08:26:56Z"],["dc.date.issued","2020"],["dc.description.abstract","Abstract Background Targeting fibroblast growth factor receptor 1 (FGFR1) is a potential treatment for squamous cell lung cancer (SQCLC). So far, treatment decision in clinical studies is based on gene amplification. However, only a minority of patients have shown durable response. Furthermore, former studies have revealed contrasting results regarding the impact of FGFR1 amplification and expression on patient's prognosis. Aims Here, we analyzed prevalence and correlation of FGFR1 gene amplification and protein expression in human lung cancer and their impact on overall survival. Materials \\u0026 Methods FGFR1 gene amplification and protein expression were analyzed by fluorescence in situ hybridization and immunohistochemistry (IHC) in 208 SQCLC and 45 small cell lung cancers (SCLC). Furthermore, FGFR1 protein expression was analyzed in 121 pulmonary adenocarcinomas (ACs). Amplification and expression were correlated to each other, clinicopathological characteristics, and overall survival. Results FGFR1 was amplified in 23% of SQCLC and 8% of SCLC. Amplification was correlated to males (P = .027) but not to overall survival. Specificity of immunostaining was verified by cellular CRISPR/Cas9 FGFR1 knockout. FGFR1 was strongly expressed in 9% of SQCLC, 35% of AC, and 4% of SCLC. Expression was correlated to females (P = .0187) and to the absence of lymph node metastasis in SQCLC (P = .018) with no significant correlation to overall survival. Interestingly, no significant correlation between amplification and expression was detected. Discussion FGFR1 gene amplification does not seem to correlate to protein expression. Conclusion We believe that patient selection for FGFR1 inhibitors in clinical studies should be reconsidered. Neither FGFR1 amplification nor expression influences patient's prognosis."],["dc.description.abstract","Fibroblast growh factor receptor 1 (FGFR1) is considered a potential molecular target in squamous cell lung cancer. However, prevalence of gene amplification as well as correlation to protein overexpression have to be established. Our work has evaluated prevalence and correlation of FGFR1 gene amplification and protein expression in 421 lung cancer patient samples. image"],["dc.description.sponsorship","Deutsche Krebshilfe Foundation"],["dc.description.sponsorship","Else‐Kroener‐Fresenius Foundation"],["dc.description.sponsorship","University Medical Center Goettingen"],["dc.description.sponsorship","Chinese Scholarship Council"],["dc.identifier.doi","10.1002/cam4.2994"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17450"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82118"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","2045-7634"],["dc.relation.issn","2045-7634"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Fibroblast growth factor receptor 1 gene amplification and protein expression in human lung cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e85"],["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","International Journal of Surgery. Oncology"],["dc.bibliographiccitation.lastpage","5"],["dc.bibliographiccitation.volume","5"],["dc.contributor.author","Saha, Shekhar"],["dc.contributor.author","Yao, Sha"],["dc.contributor.author","Elakad, Omar"],["dc.contributor.author","Lois, Anna-Maria"],["dc.contributor.author","Henric-Petri, Hannah"],["dc.contributor.author","Buentzel, Judith"],["dc.contributor.author","Hinterthaner, Marc"],["dc.contributor.author","Danner, Bernhard C."],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Emmert, Alexander"],["dc.contributor.author","Bohnenberger, Hanibal"],["dc.date.accessioned","2020-06-09T11:55:48Z"],["dc.date.accessioned","2021-10-27T13:22:15Z"],["dc.date.available","2020-06-09T11:55:48Z"],["dc.date.available","2021-10-27T13:22:15Z"],["dc.date.issued","2020"],["dc.description.abstract","Background: UDP-glucose-6-dehydrogenase (UGDH) plays an important role in the production of hyaluronic acid, an extracellular matrix component that is responsible for the promotion of normal cellular growth and migration. Increased levels of UGDH have been linked to the progression of epithelial cancers, such as those of the breast, colon and prostate. Therefore we aimed to analyze if the expression level of UGDH does also influence patients survival of lung cancer patients. Methods: UGDH expression levels were analyzed by immunohistochemistry in 96 samples of pulmonary adenocarcinoma (AC), 84 cases of squamous cell lung carcinoma (SQCLC) and 33 samples of small cell lung cancer (SCLC) and correlated with clinicopathologic characteristics and patient outcome. Results: UGDH was expressed in 62.5% cases of AC, 70.2% cases of SQCLC, and 48.5% cases of SCLC. In AC, expression of UGDH was significantly associated with lymph node metastasis and worse overall survival of the affected patients. However, UGDH expression had no significant correlation to prognosis in SQCLC or SCLC patients. Conclusions: In our study, expression of UGDH was associated with worse prognosis of patients with pulmonary adenocarcinoma so that expression of UGDH might help to guide treatment decisions. Furthermore, UGDH might present a potential novel drug target in AC as it displays inhibitable catalytic activity."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2020"],["dc.identifier.doi","10.1097/IJ9.0000000000000085"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17377"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/92078"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.relation.issn","2471-3864"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","UDP-glucose 6-dehydrogenase expression as a predictor of survival in patients with pulmonary adenocarcinoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","47"],["dc.bibliographiccitation.issue","04"],["dc.bibliographiccitation.journal","Open Journal of Thoracic Surgery"],["dc.bibliographiccitation.lastpage","56"],["dc.bibliographiccitation.volume","06"],["dc.contributor.author","Emmert, Alexander"],["dc.contributor.author","Oellerich, Angelika"],["dc.contributor.author","Füzesi, Laszlo"],["dc.contributor.author","Beushausen, Regina Waldmann-"],["dc.contributor.author","Schöndube, Friedrich A."],["dc.contributor.author","Bohnenberger, Hanibal"],["dc.contributor.author","Danner, Bernhard C."],["dc.date.accessioned","2019-07-09T11:43:03Z"],["dc.date.available","2019-07-09T11:43:03Z"],["dc.date.issued","2016"],["dc.description.abstract","Pigment epithelium-derived factor (PEDF), a potent antiangiogenesis agent, is a multifunctional protein with important roles in regulation of inflammation and angiogenesis. It has recently attracted attention for targeting tumor cells in several types of tumors. PECAM-1 is an integral membrane protein, a cell adhesion molecule with proangiogenic activity and plays an important role in the process of angiogenesis. The correlation between proangiogenic activity PECAM-1 and antiangiogenic activity PEDF in Non-Small-Cell-Lung Cancer has not been reported. The present study was designed to evaluate using immunohistochemical techniques and multivariate analysis the interplay between PECAM-1 and PEDF in NSCLC, especially in adenocarcinoma and in squamous cell carcinoma stage IA-IIIB. Analyzing the mixed study collectively (n = 69), there was no significant correlation (p = 0.553) between PECAM-1 signal and PEDF area. Only including patients with adenocarcinoma (Figure 2), we found a positive correlation between PECAM-1 signal and PEDF area (p = 0.025). In patients with squamous cell carcinoma, we did not find a significant correlation between PECAM-1 signal and PEDF area (p = 0.530). In patients with squamous cell carcinoma, PECAM-1 and PEDF show a significant different expression pattern, measured via staining intensity (p = 0.013). These results might support the hypothesis that squamous cell carcinomas heavily rely on angiogenic processes."],["dc.identifier.doi","10.4236/ojts.2016.64007"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14092"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58813"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2164-3067"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Interplay between Platelet Endothelial Cell Adhesion Molecule-1 and Pigment Epithelium-Derived Factor in Non-Small-Cell-Lung Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Metabolites"],["dc.bibliographiccitation.volume","12"],["dc.contributor.affiliation","Li, Yuchan; 1Institute of Pathology, University Medical Center, 37075 Göttingen, Germany; yuchan.li@stud.uni-goettingen.de (Y.L.); omarakkad14@gmail.com (O.E.); yaosha2016@gmail.com (S.Y.); carmelo.ferrai@med.uni-goettingen.de (C.F.); philipp.stroebel@med.uni-goettingen.de (P.S.)"],["dc.contributor.affiliation","Elakad, Omar; 1Institute of Pathology, University Medical Center, 37075 Göttingen, Germany; yuchan.li@stud.uni-goettingen.de (Y.L.); omarakkad14@gmail.com (O.E.); yaosha2016@gmail.com (S.Y.); carmelo.ferrai@med.uni-goettingen.de (C.F.); philipp.stroebel@med.uni-goettingen.de (P.S.)"],["dc.contributor.affiliation","Yao, Sha; 1Institute of Pathology, University Medical Center, 37075 Göttingen, Germany; yuchan.li@stud.uni-goettingen.de (Y.L.); omarakkad14@gmail.com (O.E.); yaosha2016@gmail.com (S.Y.); carmelo.ferrai@med.uni-goettingen.de (C.F.); philipp.stroebel@med.uni-goettingen.de (P.S.)"],["dc.contributor.affiliation","von Hammerstein-Equord, Alexander; 4Department of Thoracic and Cardiovascular Surgery, University Medical Center, 37075 Göttingen, Germany; alexander.hammerstein@med.uni-goettingen.de (A.v.H.-E.); marc.hinterthaner@med.uni-goettingen.de (M.H.); bernd.danner@med.uni-goettingen.de (B.C.D.)"],["dc.contributor.affiliation","Hinterthaner, Marc; 4Department of Thoracic and Cardiovascular Surgery, University Medical Center, 37075 Göttingen, Germany; alexander.hammerstein@med.uni-goettingen.de (A.v.H.-E.); marc.hinterthaner@med.uni-goettingen.de (M.H.); bernd.danner@med.uni-goettingen.de (B.C.D.)"],["dc.contributor.affiliation","Danner, Bernhard C.; 4Department of Thoracic and Cardiovascular Surgery, University Medical Center, 37075 Göttingen, Germany; alexander.hammerstein@med.uni-goettingen.de (A.v.H.-E.); marc.hinterthaner@med.uni-goettingen.de (M.H.); bernd.danner@med.uni-goettingen.de (B.C.D.)"],["dc.contributor.affiliation","Ferrai, Carmelo; 1Institute of Pathology, University Medical Center, 37075 Göttingen, Germany; yuchan.li@stud.uni-goettingen.de (Y.L.); omarakkad14@gmail.com (O.E.); yaosha2016@gmail.com (S.Y.); carmelo.ferrai@med.uni-goettingen.de (C.F.); philipp.stroebel@med.uni-goettingen.de (P.S.)"],["dc.contributor.affiliation","Ströbel, Philipp; 1Institute of Pathology, University Medical Center, 37075 Göttingen, Germany; yuchan.li@stud.uni-goettingen.de (Y.L.); omarakkad14@gmail.com (O.E.); yaosha2016@gmail.com (S.Y.); carmelo.ferrai@med.uni-goettingen.de (C.F.); philipp.stroebel@med.uni-goettingen.de (P.S.)"],["dc.contributor.affiliation","Küffer, Stefan; 1Institute of Pathology, University Medical Center, 37075 Göttingen, Germany; yuchan.li@stud.uni-goettingen.de (Y.L.); omarakkad14@gmail.com (O.E.); yaosha2016@gmail.com (S.Y.); carmelo.ferrai@med.uni-goettingen.de (C.F.); philipp.stroebel@med.uni-goettingen.de (P.S.)"],["dc.contributor.affiliation","Bohnenberger, Hanibal; 1Institute of Pathology, University Medical Center, 37075 Göttingen, Germany; yuchan.li@stud.uni-goettingen.de (Y.L.); omarakkad14@gmail.com (O.E.); yaosha2016@gmail.com (S.Y.); carmelo.ferrai@med.uni-goettingen.de (C.F.); philipp.stroebel@med.uni-goettingen.de (P.S.)"],["dc.contributor.author","Li, Yuchan"],["dc.contributor.author","Elakad, Omar"],["dc.contributor.author","Yao, Sha"],["dc.contributor.author","von Hammerstein-Equord, Alexander"],["dc.contributor.author","Hinterthaner, Marc"],["dc.contributor.author","Danner, Bernhard C."],["dc.contributor.author","Ferrai, Carmelo"],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Küffer, Stefan"],["dc.contributor.author","Bohnenberger, Hanibal"],["dc.date.accessioned","2022-08-04T08:28:51Z"],["dc.date.available","2022-08-04T08:28:51Z"],["dc.date.issued","2022-07-15"],["dc.date.updated","2022-08-03T15:44:46Z"],["dc.description.abstract","Activating KRAS mutations occur in about 30% of pulmonary adenocarcinoma (AC) cases and the discovery of specific inhibitors of G12C-mutated KRAS has considerably improved the prognosis for a subgroup of about 14% of non-small cell lung cancer (NSCLC) patients. However, even in patients with a KRAS G12C mutation, the overall response rate only reaches about 40% and mutations other than G12C still cannot be targeted. Despite the fact that one-carbon metabolism (1CM) and epigenetic regulation are known to be dysregulated by aberrant KRAS activity, we still lack evidence that co-treatment with drugs that regulate these factors might ameliorate response rates and patient prognosis. In this study, we show a direct dependency of Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) and Enhancer of Zeste Homolog 2 (EZH2) expression on mutationally activated KRAS and their prognostic relevance in KRAS-mutated AC. We show that aberrant KRAS activity generates a vulnerability of AC cancer cell lines to both MTHFD2 and EZH2 inhibitors. Importantly, co-inhibition of both factors was synergistically effective and comparable to KRASG12C inhibition alone, paving the way for their use in a therapeutic approach for NSCLC cancer patients."],["dc.description.sponsorship","Deutsche Krebshilfe Foundation"],["dc.description.sponsorship","University Medical Center Göttingen"],["dc.description.sponsorship","Else-Kröner-Fresenius-Foundation"],["dc.description.sponsorship","Chinese Scholarship Counsil"],["dc.description.sponsorship","DFG"],["dc.identifier.doi","10.3390/metabo12070652"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112626"],["dc.language.iso","en"],["dc.relation.eissn","2218-1989"],["dc.rights","CC BY 4.0"],["dc.title","Regulation and Therapeutic Targeting of MTHFD2 and EZH2 in KRAS-Mutated Human Pulmonary Adenocarcinoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Journal of Thoracic Oncology"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Bohnenberger, Hanibal"],["dc.contributor.author","Yepes, Diego"],["dc.contributor.author","Pan, Kuan-Ting"],["dc.contributor.author","Emmert, Alexander"],["dc.contributor.author","Henric-Petri, Hannah"],["dc.contributor.author","Bremmer, Felix"],["dc.contributor.author","Strecker, Jasmin"],["dc.contributor.author","Lois, Anna-Maria"],["dc.contributor.author","Fischer, Lucas"],["dc.contributor.author","Kueffer, Stefan"],["dc.contributor.author","Hinterthaner, Marc"],["dc.contributor.author","Wolff, Hendrik"],["dc.contributor.author","Canis, Martin"],["dc.contributor.author","Sebastian, Martin"],["dc.contributor.author","Danner, Bernd"],["dc.contributor.author","Stroebel, Philipp"],["dc.contributor.author","Serve, Hubert"],["dc.contributor.author","Urlaub, Henning"],["dc.contributor.author","Oellerich, Thomas"],["dc.date.accessioned","2018-11-07T09:51:51Z"],["dc.date.available","2018-11-07T09:51:51Z"],["dc.date.issued","2015"],["dc.format.extent","S293"],["dc.identifier.isi","000370365101087"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35995"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.publisher.place","New york"],["dc.relation.issn","1556-1380"],["dc.relation.issn","1556-0864"],["dc.title","Proteomic Profiling of Pulmonary Cancer with Squamous Cell Histology"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]